title: Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study.
abstract: In order to compare the effects of interferon versus hydroxyurea for the treatment of chronic myelogenous leukaemia (CML), 58 CML patients, having received no previous treatment, were randomized into two treatment groups (hydroxyurea or interferon) for an open multicentre study from 1 May 1987 until 1 July 1990. Fifty patients were evaluable: 24 in the interferon group and 26 in the hydroxyurea group. Haematological response was obtained in 16/24 interferon-treated patients and 23/26 hydroxyurea patients. Failure to obtain haematological remissions occurred in eight of 24 interferon-treated patients and in three of 26 hydroxyurea patients. Four interferon-treated patient failures and one hydroxyurea-treated failure were due to drug intolerance. Progression occurred in one interferon-treated patient and in three patients given hydroxyurea. Fourteen of 16 patients in the interferon group and 17/23 in the hydroxyurea group continue on study and show no progression.
authors.affiliation: Hôpital Haut Leveque, Pessac, France.
authors.forename: A
authors.initials: A
authors.lastname: Broustet
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: D
authors.initials: D
authors.lastname: Fiere
authors.forename: J
authors.initials: J
authors.lastname: Jaubert
authors.forename: J
authors.initials: J
authors.lastname: Reynaud
authors.forename: J
authors.initials: J
authors.lastname: Pris
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: C
authors.initials: C
authors.lastname: Charrin
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Wen
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006918:Hydroxyurea